
Seres Therapeutics (MCRB) Stock Forecast & Price Target
Seres Therapeutics (MCRB) Analyst Ratings
Bulls say
Seres Therapeutics Inc. has demonstrated significant progress in its development pipeline, notably receiving positive feedback from the FDA regarding the Phase 2 plan for SER-155, which is likely to enhance expectations for regulatory approval. The company has solid financial health, with a cash runway extended to the second quarter of 2026 following a strategic 25% workforce reduction. Furthermore, ongoing efforts to secure a partnership for SER-155 underscore the company’s commitment to advancing its microbiome therapeutics platform, indicating potential for future growth.
Bears say
Seres Therapeutics Inc faces significant commercial risks, particularly concerning its product SER-109, which may generate revenues that fall short of both internal and consensus estimates, posing potential downside to the company's financial outlook. The requirement for additional safety or manufacturing data by the FDA could lead to delays in SER-109's approval process, further exacerbating these risks and impacting the company's market value. As a clinical-stage biotechnology company, Seres is expected to pursue additional capital raises, which could dilute current investors' stakes and negatively affect the current share price.
This aggregate rating is based on analysts' research of Seres Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Seres Therapeutics (MCRB) Analyst Forecast & Price Prediction
Start investing in Seres Therapeutics (MCRB)
Order type
Buy in
Order amount
Est. shares
0 shares